Skip to main content

Advertisement

Table 2 Ongoing studies with crizotinib

From: Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

NCT Number Combination Drugs PHASES URL
NCT00932451 Drug: PF-02341066 Phase2 https://ClinicalTrials.gov/show/NCT00932451
NCT00932893 Drug: PF-02341066 Phase3 https://ClinicalTrials.gov/show/NCT00932893F
Drug: Pemetrexed
Drug: Docetaxel
NCT01154140 Drug: treatment Phase3 https://ClinicalTrials.gov/show/NCT01154140
Drug: treatment
NCT01685060 Drug: LDK378 Phase2 https://ClinicalTrials.gov/show/NCT01685060
NCT01121575 Drug: PF-02341066 Phase1 https://ClinicalTrials.gov/show/NCT01121575
Drug: PF-00299804
Drug: PF-02341066
Drug: PF-00299804
NCT00965731 Drug: Erlotinib Phase1 https://ClinicalTrials.gov/show/NCT00965731
Drug: PF-02341066
NCT02435108 Drug: crizotinib Phase2 https://ClinicalTrials.gov/show/NCT02435108